Filspari fda approval?

What is Filspari, and when did the FDA approve it?

Filspari (sparsentan) is an FDA-approved treatment for primary IgA nephropathy (IgAN) at risk of rapid disease progression. The FDA approval came in 2023. [1]

Who makes Filspari?

Filspari is marketed by CSL Vifor. [1]

What is sparsentan approved to treat (and for whom)?

Filspari (sparsentan) is approved for adults with primary IgA nephropathy who are at risk of rapid disease progression. [1]

What does the FDA approval mean for patients (what they can expect next)?

After an FDA approval, the next practical steps for patients are typically to confirm eligibility (diagnosis and risk criteria used in the labeling) with their nephrologist and then start treatment under prescribed dosing and monitoring requirements in the drug label. The approval itself establishes the drug’s use for the indicated population. [1]

Where can I find the official FDA details?

For the most direct labeling and approval information (including indication language), you can also check the drug’s FDA materials and labeling, and cross-reference timelines using DrugPatentWatch.com. [1]

Sources:
[1] https://www.drugpatentwatch.com/p/brand/filspari